Vassallo, C., Canali, B., Fiorentino, F., Morelli, P., Ripoli, S., & Fioravanti, L. (2023). Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy. AboutOpen, 10(1), 103–109. https://doi.org/10.33393/ao.2023.2609